Paweł Domagała

Dr. Paweł Domagała


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
THTomasz Huzarski
Tomasz Huzarski
TBTomasz Byrski
Tomasz Byrski
JGJacek Gronwald
Jacek Gronwald
BGBohdan Górski
Bohdan Górski
PDPawel Domagala
Pawel Domagala
Steven NarodSteven Narod
Steven Narod
Purpose To estimate 10-year overall survival (OS) rates for patients with early-onset breast cancer, with and without a BRCA1 mutation, and to identify prognostic factors among those with BRCA1-positive breast cancer. Patients and Methods A total of 3,345 women with stage I to III breast cancer, age ≤ 50 years, were tested for three founder mutations in BRCA1. Information on tumor characteristics and treatments received was retrieved from medical records. Dates of death were obtained from the vital statistics registry. Survival curves for the mutation-positive and -negative subcohorts were compared. Predictors of OS were determined using the Cox proportional hazards model. Results Of the 3,345 patients enrolled onto the study, 233 (7.0%) carried a BRCA1 mutation. The 10-year survival rate for mutation carriers was 80.9% (95% CI, 75.4% to 86.4%); for noncarriers, it was 82.2% (95% CI, 80.5% to 83.7%). The adjusted hazard ratio (HR) associated with carrying a BRCA1 mutation was 1.81 (95% CI, 1.26 to 2.61). Among BRCA1 carriers with a small (< 2 cm) node-negative tumor, the 10-year survival rate was 89.9%. Among BRCA1 mutation carriers, positive lymph node status was a strong predictor of mortality (adjusted HR, 4.1; 95% CI, 1.8 to 8.9). Oophorectomy was associated with improved survival in BRCA1 carriers (adjusted HR, 0.30; 95% CI, 0.12 to 0.75). Conclusion The 10-year survival rate among women with breast cancer and a BRCA1 mutation is similar to that of patients without a BRCA1 mutation. Among women with a BRCA1 mutation, survival was much improved after oophorectomy.

17 March 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
PDPawel Domagala
Pawel Domagala
THTomasz Huzarski
Tomasz Huzarski
JLJan Lubiński
Jan Lubiński
KGKarol Gugala
Karol Gugala
WDWenancjusz Domagala
Wenancjusz Domagala

13 November 2012 in British Journal of Cancer
Verified
Journal Article
Open access
TCthe Polish Hereditary Prostate Cancer Consortium
the Polish Hereditary Prostate Cancer Consortium
CCCezary Cybulski
Cezary Cybulski
DWD Wokołorczyk
D Wokołorczyk
WKW Kluźniak
W Kluźniak
AJAnna Jakubowska
Anna Jakubowska
JLJan Lubiński
Jan Lubiński
Background: Methods: Results: Conclusion:

8 January 2013 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
UTUrszula Teodorczyk
Urszula Teodorczyk
CCCezary Cybulski
Cezary Cybulski
DWDominika Wokołorczyk
Dominika Wokołorczyk
AJAnna Jakubowska
Anna Jakubowska
TSTeresa Starzyńska
Teresa Starzyńska
JLJan Lubiński
Jan Lubiński

Verified
Journal Article
Open access
PDF file
Marek DrozdzikMarek Drozdzik
Marek Drozdzik
SSSylwia Sylwia Szeląg-Pieniek
Sylwia Sylwia Szeląg-Pieniek
JGJustyna Grzegółkowska
Justyna Grzegółkowska
JŁJoanna Łapczuk-Romańska
Joanna Łapczuk-Romańska
MPMariola Post
Mariola Post
MKMateusz Kurzawski
Mateusz Kurzawski
Membrane monocarboxylate transporter 1 (SLC16A1/MCT1) plays an important role in hepatocyte homeostasis, as well as drug handling. However, there is no available information about the impact of liver pathology on the transporter levels and function. The study was aimed to quantify SLC16A1 mRNA (qRT-PCR) and MCT1 protein abundance (liquid chromatography–tandem mass spectrometry (LC¬¬–MS/MS)) in the livers of patients diagnosed, according to the standard clinical criteria, with hepatitis C, primary biliary cirrhosis, primary sclerosing hepatitis, alcoholic liver disease (ALD), and autoimmune hepatitis. The stage of liver dysfunction was classified according to Child–Pugh score. Downregulation of SLC16A1/MCT1 levels was observed in all liver pathology states, significantly for ALD. The progression of liver dysfunction, from Child–Pugh class A to C, involved the gradual decline in SLC16A1 mRNA and MCT1 protein abundance, reaching a clinically significant decrease in class C livers. Reduced levels of MCT1 were associated with significant intracellular lactate accumulation. The MCT1 transcript and protein did not demonstrate significant correlations regardless of the liver pathology analyzed, as well as the disease stage, suggesting posttranscriptional regulation, and several microRNAs were found as potential regulators of MCT1 abundance. MCT1 membrane immunolocalization without cytoplasmic retention was observed in all studied liver pathologies. Overall, the study demonstrates that SLC16A1/MCT1 is involved in liver pathology, especially in ALD.

24 June 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
PDPawel Domagala
Pawel Domagala
DWDominika Wokolorczyk
Dominika Wokolorczyk
CCCezary Cybulski
Cezary Cybulski
THTomasz Huzarski
Tomasz Huzarski
JLJan Lubiński
Jan Lubiński
WDWenancjusz Domagala
Wenancjusz Domagala